Special Issue "Cancer Vaccines and Immunotherapy"

Quicklinks

A special issue of Cancers (ISSN 2072-6694).

Deadline for manuscript submissions: closed (30 May 2011)

Special Issue Editors

Guest Editor
Prof. Dr. W. Martin Kast
Walter A. Richter Cancer Research Chair, Professor of Molecular Microbiology & Immunology, Obstetrics & Gynecology and Urology, Norris Comprehensive Cancer Center (NRT 7507), University of Southern California, 1450 Biggy Street, MC 9601, Los Angeles, CA90033, USA
Website: http://pibbs.usc.edu/faculty/profile/?fid=236
E-Mail: mkast@usc.edu
Phone: +1 323 442 3870
Fax: +1 323 442 7760
Interests: design of HPV immunotherapeutics; developing new and effective therapies for cervical cancer; prostate cancer and melanoma

Guest Editor
Prof. Dr. Maurizio Chiriva-Internati
Division of Hematology and Oncology, Texas Tech University Health Sciences Center, 3601 4th St STOP, 6591, Lubbock, TX 79430, USA
E-Mail: maurizio.chiriva@ttuhsc.edu
Phone: +1-806-743-3155.ext. 279
Fax: +1-806-743-3148
Interests: tumor immunology, developing therapeutic and preventive tumor vaccine; ovarian cancer, multiple myeloma, breast cancer, prostate cancer

Special Issue Information

Dear Colleagues,

Despite intense ongoing research, many cancers are still incurable. Tumor cells induce immune tolerance, which represents a major obstacle for the application of cancer immunotherapy. Therefore, a current challenge for the field of cancer immunotherapy is to develop new approaches capable of breaking tumor-induced tolerance and inducing the (re-)activation of spontaneous and/or vaccine-triggered anti-tumor immune responses.

The exciting news this year is that we are now experiencing that cancer immunotherapy is finally becoming part of FDA approved cancer therapies. Cancer immunotherapy may provide a more effective and safer alternative approach to standard treatments, since unlike these currently available standard treatments, vaccines exploit natural anti-tumor immune surveillance, and offer the potential to provide durable control of primary and metastatic cancers.

Therefore, we invite research and review manuscripts in the field of cancer vaccines/cancer immunotherapy and topics related to new tumor antigen discovery, novel developments in therapeutic and preventive cancer vaccines, T regulatory cells, dendritic cell vaccines, T cell vaccines, B cell vaccines, pharmacological therapy, gene therapy, tumor-associated cancer testis antigens, immunosuppressive mechanisms, immune-regulatory applications and the regulation of immune surveillance against cancer as well as multi modality cancer approaches in which cancer vaccines/cancer immunotherapies play a role.

We are looking forward to your vital contributions.

Dr. W. Martin Kast
Dr. Maurizio Chiriva Internati
Guest Editors

Keywords

  • cytotoxic T lymphocytes
  • dendritic cells
  • therapeutic cancer vaccines
  • preventive cancer vaccines
  • cancer immunotherapy
  • immunomodulation

Published Papers (19 papers)

Download All Papers
Sort by:
Display options:
Select articles Export citation of selected articles as:
Select/unselect all
Displaying article 1-19
p. 581-600
by , , , , ,  and
Cancers 2012, 4(2), 581-600; doi:10.3390/cancers4020581
Received: 18 May 2012; in revised form: 13 June 2012 / Accepted: 14 June 2012 / Published: 18 June 2012
Show/Hide Abstract | PDF Full-text (804 KB) | HTML Full-text | XML Full-text
(This article belongs to the Special Issue Cancer Vaccines and Immunotherapy)
p. 4191-4211
by , , , , , , , ,  and
Cancers 2011, 3(4), 4191-4211; doi:10.3390/cancers3044191
Received: 17 September 2011; in revised form: 31 October 2011 / Accepted: 9 November 2011 / Published: 25 November 2011
Show/Hide Abstract | PDF Full-text (1337 KB) | HTML Full-text | XML Full-text
(This article belongs to the Special Issue Cancer Vaccines and Immunotherapy)
abstract graphic
p. 4151-4169
by , , , ,  and
Cancers 2011, 3(4), 4151-4169; doi:10.3390/cancers3044151
Received: 17 October 2011; in revised form: 3 November 2011 / Accepted: 7 November 2011 / Published: 11 November 2011
Show/Hide Abstract | Cited by 3 | PDF Full-text (723 KB) | HTML Full-text | XML Full-text
(This article belongs to the Special Issue Cancer Vaccines and Immunotherapy)
p. 4139-4150
by , ,  and
Cancers 2011, 3(4), 4139-4150; doi:10.3390/cancers3044139
Received: 6 September 2011; in revised form: 19 October 2011 / Accepted: 19 October 2011 / Published: 10 November 2011
Show/Hide Abstract | PDF Full-text (184 KB) | HTML Full-text | XML Full-text
(This article belongs to the Special Issue Cancer Vaccines and Immunotherapy)
p. 3991-4009
by ,  and
Cancers 2011, 3(4), 3991-4009; doi:10.3390/cancers3043991
Received: 15 August 2011; in revised form: 13 October 2011 / Accepted: 14 October 2011 / Published: 25 October 2011
Show/Hide Abstract | Cited by 1 | PDF Full-text (212 KB) | HTML Full-text | XML Full-text
(This article belongs to the Special Issue Cancer Vaccines and Immunotherapy)
p. 3856-3893
by  and
Cancers 2011, 3(4), 3856-3893; doi:10.3390/cancers3043856
Received: 16 August 2011; in revised form: 24 September 2011 / Accepted: 27 September 2011 / Published: 13 October 2011
Show/Hide Abstract | Cited by 13 | PDF Full-text (369 KB) | HTML Full-text | XML Full-text
(This article belongs to the Special Issue Cancer Vaccines and Immunotherapy)
p. 3687-3713
by  and
Cancers 2011, 3(3), 3687-3713; doi:10.3390/cancers3033687
Received: 1 August 2011; in revised form: 9 September 2011 / Accepted: 14 September 2011 / Published: 22 September 2011
Show/Hide Abstract | Cited by 5 | PDF Full-text (333 KB) | HTML Full-text | XML Full-text
(This article belongs to the Special Issue Cancer Vaccines and Immunotherapy)
p. 3461-3495
by , ,  and
Cancers 2011, 3(3), 3461-3495; doi:10.3390/cancers3033461
Received: 1 August 2011; in revised form: 26 August 2011 / Accepted: 29 August 2011 / Published: 2 September 2011
Show/Hide Abstract | Cited by 2 | PDF Full-text (379 KB) | HTML Full-text | XML Full-text
(This article belongs to the Special Issue Cancer Vaccines and Immunotherapy)
abstract graphic
p. 3370-3393
by  and
Cancers 2011, 3(3), 3370-3393; doi:10.3390/cancers3033370
Received: 28 July 2011; in revised form: 12 August 2011 / Accepted: 15 August 2011 / Published: 19 August 2011
Show/Hide Abstract | PDF Full-text (298 KB) | HTML Full-text | XML Full-text | Supplementary Files
(This article belongs to the Special Issue Cancer Vaccines and Immunotherapy)
p. 3225-3241
by , , , , , ,  and
Cancers 2011, 3(3), 3225-3241; doi:10.3390/cancers3033225
Received: 7 July 2011; in revised form: 2 August 2011 / Accepted: 3 August 2011 / Published: 10 August 2011
Show/Hide Abstract | Cited by 3 | PDF Full-text (500 KB) | HTML Full-text | XML Full-text
(This article belongs to the Special Issue Cancer Vaccines and Immunotherapy)
abstract graphic
p. 3169-3188
by ,  and
Cancers 2011, 3(3), 3169-3188; doi:10.3390/cancers3033169
Received: 3 June 2011; in revised form: 15 July 2011 / Accepted: 1 August 2011 / Published: 8 August 2011
Show/Hide Abstract | PDF Full-text (484 KB) | HTML Full-text | XML Full-text
(This article belongs to the Special Issue Cancer Vaccines and Immunotherapy)
abstract graphic
p. 3114-3142
by ,  and
Cancers 2011, 3(3), 3114-3142; doi:10.3390/cancers3033114
Received: 8 June 2011; in revised form: 27 July 2011 / Accepted: 28 July 2011 / Published: 5 August 2011
Show/Hide Abstract | Cited by 4 | PDF Full-text (270 KB) | HTML Full-text | XML Full-text
(This article belongs to the Special Issue Cancer Vaccines and Immunotherapy)
p. 3055-3072
by  and
Cancers 2011, 3(3), 3055-3072; doi:10.3390/cancers3033055
Received: 7 June 2011; in revised form: 22 July 2011 / Accepted: 26 July 2011 / Published: 29 July 2011
Show/Hide Abstract | Cited by 3 | PDF Full-text (527 KB) | HTML Full-text | XML Full-text
(This article belongs to the Special Issue Cancer Vaccines and Immunotherapy)
abstract graphic
p. 3073-3103
by ,  and
Cancers 2011, 3(3), 3073-3103; doi:10.3390/cancers3033073
Received: 1 July 2011; in revised form: 25 July 2011 / Accepted: 26 July 2011 / Published: 29 July 2011
Show/Hide Abstract | Cited by 3 | PDF Full-text (2632 KB) | HTML Full-text | XML Full-text
(This article belongs to the Special Issue Cancer Vaccines and Immunotherapy)
abstract graphic
p. 2904-2954
by , ,  and
Cancers 2011, 3(3), 2904-2954; doi:10.3390/cancers3032904
Received: 26 May 2011; in revised form: 1 July 2011 / Accepted: 7 July 2011 / Published: 18 July 2011
Show/Hide Abstract | PDF Full-text (357 KB) | HTML Full-text | XML Full-text
(This article belongs to the Special Issue Cancer Vaccines and Immunotherapy)
abstract graphic
p. 2870-2885
by , , , , ,  and
Cancers 2011, 3(3), 2870-2885; doi:10.3390/cancers3032870
Received: 24 May 2011; in revised form: 27 June 2011 / Accepted: 6 July 2011 / Published: 13 July 2011
Show/Hide Abstract | Cited by 5 | PDF Full-text (771 KB) | HTML Full-text | XML Full-text
(This article belongs to the Special Issue Cancer Vaccines and Immunotherapy)
p. 2554-2596
by ,  and
Cancers 2011, 3(2), 2554-2596; doi:10.3390/cancers3022554
Received: 6 April 2011; in revised form: 24 May 2011 / Accepted: 27 May 2011 / Published: 9 June 2011
Show/Hide Abstract | Cited by 1 | PDF Full-text (417 KB) | HTML Full-text | XML Full-text
(This article belongs to the Special Issue Cancer Vaccines and Immunotherapy)
p. 2223-2242
by , , ,  and
Cancers 2011, 3(2), 2223-2242; doi:10.3390/cancers3022223
Received: 7 March 2011; in revised form: 14 April 2011 / Accepted: 19 April 2011 / Published: 28 April 2011
Show/Hide Abstract | Cited by 2 | PDF Full-text (576 KB) | HTML Full-text | XML Full-text
(This article belongs to the Special Issue Cancer Vaccines and Immunotherapy)
abstract graphic
p. 2195-2213
by  and
Cancers 2011, 3(2), 2195-2213; doi:10.3390/cancers3022195
Received: 14 March 2011; in revised form: 14 April 2011 / Accepted: 19 April 2011 / Published: 26 April 2011
Show/Hide Abstract | Cited by 2 | PDF Full-text (229 KB) | HTML Full-text | XML Full-text
(This article belongs to the Special Issue Cancer Vaccines and Immunotherapy)
Select/unselect all
Displaying article 1-19
Select articles Export citation of selected articles as:

Last update: 25 February 2014

Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert